FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2307723713> ?p ?o ?g. }

• W2307723713 endingPage "2673" @default.
• W2307723713 startingPage "2673" @default.
• W2307723713 abstract "Abstract Diffuse large B-cell lymphoma (DLBCL) is the largest lymphoma subtype representing approximately one-third of all cases of non-Hodgkin's lymphoma. Gene expression profiling showed that DLBCL can be stratified into activated B-cell (ABC) or germinal center B-cell (GCB) subtypes (Alizadeh et al., Nature 2000). The overall five year survival rate is only approximately 50% (Shaffer et al., Annu. Rev. Immunol. 2012), thus a medical need exits for the treatment of this disease, particularly for patients who relapse after the first line chemoimmunotherapy regimen. Idelalisib is an investigational, highly selective oral inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta isoform. PI3K delta signaling is required for B lymphocyte activation, proliferation and survival and is dysregulated in several B-cell malignancies. We investigated the activity of idelalisib and ibrutinib, an inhibitor of Bruton's tyrosine kinase, on the inhibition of proliferation against a panel of 22 DLBCL (9 ABC, 13 GCB) and 3 transformed follicular lymphoma cell lines. Idelalisib has potent activity (EC50&lt;300nM) against 3 of 9 (33%) ABC, 3 of 13 (23%) GCB DLBCL and 1 of 3 (33%) transformed follicular lymphoma cell lines at clinically achievable concentrations (culture media protein binding adjusted Cmax 421nM). In contrast, ibrutinib has activity (EC50&lt;40nM) against only 3 of 9 (33%) ABC DLBCL cell lines at clinically achievable concentrations (culture media protein binding adjusted Cmax 48nM). Interestingly, the same three ABC DLBCL cells lines are sensitive to both idelalisib and ibrutinib. Although all of the B-lymphoma cell lines express multiple PI3K isoforms, the PI3K delta isoform is the most highly expressed across all malignant B lymphoma cell lines evaluated. We show that PI3K delta is essential for proliferation in the idelalisib sensitive cell lines using PI3K alpha, beta, or delta isoform selective inhibitors. Further, we demonstrate that idelalisib blocks AKT and RPS6 phosphorylation. Activating mutations in CD79 subunits of the B-cell receptor are associated with sensitivity to idelalisib and ibrutinib in ABC DLBCL cell lines. The absence of PTEN protein in GCB DLBCL cell lines does not correlate with increased sensitivity to idelalisib. Baseline and drug treatment gene expression analysis to investigate differential pathways driving growth and survival in responding versus non responding cell types has been performed and results will be presented. These data support advancing idelalisib in clinical trials for the treatment of a select subgroup of DLBCL patient population Citation Format: Jia Y. Liu, Tom Kenney, Leslie Butterworth, Adam Kashishian, Sarah Meadows, Peng Yue, Li Li, Kathleen Keegan, Christophe Quéva, Stacey Tannheimer. Idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2673. doi:10.1158/1538-7445.AM2015-2673" @default.
• W2307723713 created "2016-06-24" @default.
• W2307723713 creator A5003025066 @default.
• W2307723713 creator A5027475930 @default.
• W2307723713 creator A5029983978 @default.
• W2307723713 creator A5034859202 @default.
• W2307723713 creator A5042733471 @default.
• W2307723713 creator A5048884066 @default.
• W2307723713 creator A5064932456 @default.
• W2307723713 creator A5067308803 @default.
• W2307723713 creator A5067886194 @default.
• W2307723713 creator A5071709307 @default.
• W2307723713 date "2015-08-01" @default.
• W2307723713 modified "2023-09-23" @default.
• W2307723713 title "Abstract 2673: Idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines" @default.
• W2307723713 doi "https://doi.org/10.1158/1538-7445.am2015-2673" @default.
• W2307723713 hasPublicationYear "2015" @default.
• W2307723713 type Work @default.
• W2307723713 sameAs 2307723713 @default.
• W2307723713 citedByCount "16" @default.
• W2307723713 countsByYear W23077237132016 @default.
• W2307723713 countsByYear W23077237132017 @default.
• W2307723713 countsByYear W23077237132018 @default.
• W2307723713 countsByYear W23077237132019 @default.
• W2307723713 countsByYear W23077237132020 @default.
• W2307723713 countsByYear W23077237132021 @default.
• W2307723713 countsByYear W23077237132022 @default.
• W2307723713 crossrefType "journal-article" @default.
• W2307723713 hasAuthorship W2307723713A5003025066 @default.
• W2307723713 hasAuthorship W2307723713A5027475930 @default.
• W2307723713 hasAuthorship W2307723713A5029983978 @default.
• W2307723713 hasAuthorship W2307723713A5034859202 @default.
• W2307723713 hasAuthorship W2307723713A5042733471 @default.
• W2307723713 hasAuthorship W2307723713A5048884066 @default.
• W2307723713 hasAuthorship W2307723713A5064932456 @default.
• W2307723713 hasAuthorship W2307723713A5067308803 @default.
• W2307723713 hasAuthorship W2307723713A5067886194 @default.
• W2307723713 hasAuthorship W2307723713A5071709307 @default.
• W2307723713 hasConcept C126322002 @default.
• W2307723713 hasConcept C2777058707 @default.
• W2307723713 hasConcept C2777938653 @default.
• W2307723713 hasConcept C2778461978 @default.
• W2307723713 hasConcept C2778559949 @default.
• W2307723713 hasConcept C2779260929 @default.
• W2307723713 hasConcept C2779338263 @default.
• W2307723713 hasConcept C2779878957 @default.
• W2307723713 hasConcept C502942594 @default.
• W2307723713 hasConcept C71924100 @default.
• W2307723713 hasConcept C86803240 @default.
• W2307723713 hasConceptScore W2307723713C126322002 @default.
• W2307723713 hasConceptScore W2307723713C2777058707 @default.
• W2307723713 hasConceptScore W2307723713C2777938653 @default.
• W2307723713 hasConceptScore W2307723713C2778461978 @default.
• W2307723713 hasConceptScore W2307723713C2778559949 @default.
• W2307723713 hasConceptScore W2307723713C2779260929 @default.
• W2307723713 hasConceptScore W2307723713C2779338263 @default.
• W2307723713 hasConceptScore W2307723713C2779878957 @default.
• W2307723713 hasConceptScore W2307723713C502942594 @default.
• W2307723713 hasConceptScore W2307723713C71924100 @default.
• W2307723713 hasConceptScore W2307723713C86803240 @default.
• W2307723713 hasIssue "15_Supplement" @default.
• W2307723713 hasLocation W23077237131 @default.
• W2307723713 hasOpenAccess W2307723713 @default.
• W2307723713 hasPrimaryLocation W23077237131 @default.
• W2307723713 hasRelatedWork W1501529729 @default.
• W2307723713 hasRelatedWork W2006704637 @default.
• W2307723713 hasRelatedWork W2055742427 @default.
• W2307723713 hasRelatedWork W2307723713 @default.
• W2307723713 hasRelatedWork W2343428063 @default.
• W2307723713 hasRelatedWork W2513158839 @default.
• W2307723713 hasRelatedWork W3028202721 @default.
• W2307723713 hasRelatedWork W3096304407 @default.
• W2307723713 hasRelatedWork W4205735769 @default.
• W2307723713 hasRelatedWork W4362527376 @default.
• W2307723713 hasVolume "75" @default.
• W2307723713 isParatext "false" @default.
• W2307723713 isRetracted "false" @default.
• W2307723713 magId "2307723713" @default.
• W2307723713 workType "article" @default.